Successful treatment of thrombotic microangiopathy after haematopoietic stem cell transplantation with rituximab
Open Access
- 1 May 2007
- journal article
- Published by Wiley in British Journal of Haematology
- Vol. 137 (5) , 475-478
Abstract
Summary: Thrombotic microangiopathy (TMA) is a grave complication after haematopoietic stem cell transplantation (HSCT) and effective treatment is undefined. Five patients with postHSCT TMA, which was refractory to at least 1 week of plasma exchange and prednisolone, were treated with rituximab (375 mg/m2/week × 4). Remission was achieved in four patients, of whom three remained in remission and one had died of sepsis at a median follow‐up of 10 months. ADAMTS13 levels were low in all evaluable patients, and only one patient showed significant anti‐ADAMTS13 antibody. The levels of ADAMTS13 and anti‐ADAMTS13 antibody did not change significantly with rituximab‐induced remission.Keywords
This publication has 12 references indexed in Scilit:
- The clinical utility of ADAMTS13 activity, antigen and autoantibody assays in thrombotic thrombocytopenic purpuraBritish Journal of Haematology, 2007
- Prospective study on the behaviour of the metalloprotease ADAMTS13 and of von Willebrand factor after bone marrow transplantationBritish Journal of Haematology, 2006
- High Titer of ADAMTS13 Inhibitor Associated with Thrombotic Microangiopathy of the Gut and Skeletal Muscle after Allogeneic Hematopoietic Stem Cell TransplantationInternational Journal of Hematology, 2006
- Rituximab therapy for thrombotic thrombocytopenic purpura: A proposed study of the Transfusion Medicine/Hemostasis Clinical Trials Network with a systematic review of rituximab therapy for immune‐mediated disordersJournal of Clinical Apheresis, 2006
- ADAMTS‐13 plasma level determination uncovers antigen absence in acquired thrombotic thrombocytopenic purpura and ethnic differencesJournal of Thrombosis and Haemostasis, 2006
- Current Concepts in Thrombotic Thrombocytopenic PurpuraAnnual Review of Medicine, 2006
- Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 casesBlood, 2005
- Blood and Marrow Transplant Clinical Trials Network Toxicity Committee Consensus Summary: Thrombotic Microangiopathy after Hematopoietic Stem Cell TransplantationTransplantation and Cellular Therapy, 2005
- Thrombotic thrombocytopenic purpura‐hemolytic uremic syndrome following allogeneic HPC transplantation: a diagnostic dilemmaTransfusion, 2004
- ADAMTS13 activity in thrombotic thrombocytopenic purpura–hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patientsBlood, 2003